Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Guiba F et al. – Based on responses from this expert group, etanercept was the preferred choice for stable chronic plaque psoriasis for the majority, with infliximab preferred for more severe disease. However, there are several limitations to this pilot model, most notably the non–random selection of the expert group.

Related Articles

Pediatric psoriasis: an update
Therapeutics and Clinical Risk Management, 10/22/09    Relevance Score: 95%

FDA Approves New Drug to Treat Psoriasis
Internet Source, 11/02/09    Relevance Score: 91%

Study shows major burden of psoriasis
Internet Source, 10/29/09    Relevance Score: 91%

Prevalence of myocardial infarction in patients with psoriasis in central China
Journal of the European Academy of Dermatology and Venereology, 10/27/09    Relevance Score: 91%

Why nail psoriasis remains difficult to treat
Dermatology in Practice, 10/12/09    Relevance Score: 91%

Today in Other Drugs...keeping you current

Meta-analysis of the evidence for a partially hydrolyzed 100% whey formula for the prevention of allergic diseases
Current Medical Research and Opinion, 12/18/09

Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
Clinical Interventions in Aging, 12/18/09

Efficacy and safety of a single intrathecal methylprednisolone bolus in chronic complex regional pain syndrome
European Journal of Pain, 12/18/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address